Literature DB >> 23665506

Inhibition of mortalin expression reverses cisplatin resistance and attenuates growth of ovarian cancer cells.

Ling Yang1, Hongyan Li, Yizhou Jiang, Ji Zuo, Wen Liu.   

Abstract

The heat shock protein mortalin is frequently overexpressed in human malignancies. In this study, an assessment of mortalin expression using ovarian cancer tissue microarrays suggested that mortalin overexpression might be related to drug resistance. Using a short hairpin (sh) RNA approach, we evaluated the effect of reducing mortalin expression in vitro and in vivo. The results of our study show that elevated levels of mortalin expression increase cancer cell resistance to cisplatin-induced cytotoxicity and identify mortalin as a potential therapeutic target for improved treatment of drug-resistant ovarian cancer.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23665506     DOI: 10.1016/j.canlet.2013.05.004

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  14 in total

Review 1.  Glucose-regulated proteins in cancer: molecular mechanisms and therapeutic potential.

Authors:  Amy S Lee
Journal:  Nat Rev Cancer       Date:  2014-04       Impact factor: 60.716

2.  Relevance of mortalin to cancer cell stemness and cancer therapy.

Authors:  Chae-Ok Yun; Priyanshu Bhargava; Youjin Na; Jung-Sun Lee; Jihoon Ryu; Sunil C Kaul; Renu Wadhwa
Journal:  Sci Rep       Date:  2017-02-06       Impact factor: 4.379

3.  NF-κB p65 promotes ovarian cancer cell proliferation and migration via regulating mortalin.

Authors:  Shan Li; Mengyuan Lv; Shi Qiu; Jiaqi Meng; Wen Liu; Ji Zuo; Ling Yang
Journal:  J Cell Mol Med       Date:  2019-04-14       Impact factor: 5.310

4.  Marine Carotenoid Fucoxanthin Possesses Anti-Metastasis Activity: Molecular Evidence.

Authors:  Sukant Garg; Sajal Afzal; Ahmed Elwakeel; Damini Sharma; Navaneethan Radhakrishnan; Jaspreet Kaur Dhanjal; Durai Sundar; Sunil C Kaul; Renu Wadhwa
Journal:  Mar Drugs       Date:  2019-06-05       Impact factor: 5.118

5.  Mortaparib, a novel dual inhibitor of mortalin and PARP1, is a potential drug candidate for ovarian and cervical cancers.

Authors:  Jayarani F Putri; Priyanshu Bhargava; Jaspreet Kaur Dhanjal; Tomoko Yaguchi; Durai Sundar; Sunil C Kaul; Renu Wadhwa
Journal:  J Exp Clin Cancer Res       Date:  2019-12-19

Review 6.  Heat Shock Proteins: Agents of Cancer Development and Therapeutic Targets in Anti-Cancer Therapy.

Authors:  Chul Won Yun; Hyung Joo Kim; Ji Ho Lim; Sang Hun Lee
Journal:  Cells       Date:  2019-12-24       Impact factor: 6.600

7.  Blocking of Transient Receptor Potential Vanilloid 1 (TRPV1) promotes terminal mitophagy in multiple myeloma, disturbing calcium homeostasis and targeting ubiquitin pathway and bortezomib-induced unfolded protein response.

Authors:  Katia Beider; Evgenia Rosenberg; Valeria Dimenshtein-Voevoda; Yaarit Sirovsky; Julia Vladimirsky; Hila Magen; Olga Ostrovsky; Avichai Shimoni; Zohar Bromberg; Lola Weiss; Amnon Peled; Arnon Nagler
Journal:  J Hematol Oncol       Date:  2020-11-25       Impact factor: 17.388

8.  Mortalin/glucose-regulated protein 75 promotes the cisplatin-resistance of gastric cancer via regulating anti-oxidation/apoptosis and metabolic reprogramming.

Authors:  Yi Dai; Fan Li; Yuwen Jiao; Guoguang Wang; Tian Zhan; Yunwei Xia; Hanyang Liu; Haojun Yang; Jianping Zhang; Liming Tang
Journal:  Cell Death Discov       Date:  2021-06-11

9.  Oncogenic role of mortalin contributes to ovarian tumorigenesis by activating the MAPK-ERK pathway.

Authors:  Yingying Hu; Ling Yang; Yujie Yang; Yanyan Han; Yongbo Wang; Wen Liu; Ji Zuo
Journal:  J Cell Mol Med       Date:  2016-07-04       Impact factor: 5.310

Review 10.  Heat Shock Proteins and Ovarian Cancer: Important Roles and Therapeutic Opportunities.

Authors:  Abdullah Hoter; Hassan Y Naim
Journal:  Cancers (Basel)       Date:  2019-09-18       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.